Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Austin Sasha Lu 2. Date of Event Requiring Statement (Month/Day/Year) 01/30/2026 3. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [OLMA] (Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN STREET 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) VP of Finance and Controller 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) SAN FRANCISCO, CA 94103 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 4,488 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	01/25/2025	01/24/2031	Common Stock	2,000	$2.44	D
Stock Option (Right to Buy)	09/01/2025	08/31/2031	Common Stock	3,000	$2.44	D
Stock Option (Right to Buy)	02/01/2026	01/31/2032	Common Stock	13,000	$2.44	D
Stock Option (Right to Buy)	(1)	01/31/2033	Common Stock	6,500	$4.87	D
Stock Option (Right to Buy)	(2)	04/02/2033	Common Stock	17,500	$3.49	D
Stock Option (Right to Buy)	(3)	01/31/2034	Common Stock	51,000	$15.25	D
Stock Option (Right to Buy)	(4)	02/27/2035	Common Stock	45,000	$4.37	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Austin Sasha Lu C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN STREET SAN FRANCISCO, CA 94103			VP of Finance and Controller

Signatures

/s/ Shawnte Mitchell, Attorney-in-Fact		02/17/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
(2)	The shares underlying the option shall vest monthly over a four-year period commencing on April 3, 2023, with 1/48 of the shares vesting on the one-month anniversary of April 3, 2023 and the remainder of the shares vesting in equal installments on each one-month anniversary date thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
(3)	25% of the shares subject to the option vested on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date
(4)	25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.